Solid Q1 with 20.7% YoY growth, but QoQ momentum fades amid integration execution risk

Delivered 20.7% YoY; management claimed 21% (overstated by 0.3pp)

Delivered OPM 33.0%, matches claimed EBITDA 33%

Delivered 27.8% YoY PAT growth, INR 193.7 Cr (on-target)

INR 294 Cr reported + INR 20 Cr = INR 314 Cr, ~35% EBITDA margin; plausible but unaudited

Management explicitly reconfirmed expected EBITDA run-rate post-close; no Q1 partial contribution disclosed

Post-close assessment: TruBridge revenue now $300M run-rate (vs $340M pre-close forecast); drivers: conservative rev rec ($2-3M/qtr), service line elimination ($8M/qtr), customer discounts ($2-3M/qtr)

FY30 INR 3,000 Cr EBITDA reconfirmed; added condition: achievable without dilution (except ESOPs) or net debt increase—de facto stricter credibility bar than prior call

Management said 'aspiration not guidance' multiple times; declined to forecast TruBridge growth or pro-forma combined revenue, citing need for 2-3 quarters of visibility

Legacy IKS tax rate: 22-23% for FY27; combined pro-forma tax rate deferred to next call (implies TruBridge tax profile still being analyzed)

12% market growth is the aspiration floor, not guidance. Margin growth driven by operating leverage (12% revenue growth on 4.2% headcount increase), NOT forex (Q1 forex was neutral). IKS aspires to 12%+ on legacy business; TruBridge growth outlook deferred.

Three SLM models: standalone (low latency/cost), distilled-from-LLM (teacher model), hierarchical (SLM for intent, LLM for reasoning). Explainability via knowledge graphs from ARAI acquisition. Token utilization may drop 60% vs pure-LLM approach, but can't quantify today.

Strategic 18-month thematic hunt to build integrated system of action + system of record for rural market without competing with Epic in traditional market. TruBridge attractive: 30%+ market share, large TAM, service mix similar to ambulatory. Acquisitions must pass: strategic thesis first, then financial viability, accretive pricing, reasonable leverage.

Yes, absolutely. EBITDA confirmed at $68M despite revenue reset, so margin expansion more than offsets revenue decline. Perhaps even more accretive than pre-close forecast.

Legacy IKS continues 12%+ aspiration. Significant cross-sell opportunity into TruBridge 2,000-customer base, but too early to quantify. Will provide TruBridge growth outlook after 2-3 quarters of ownership.

Low-hanging fruit: technology leverage (already built), offshore human-in-the-loop, operational SG&A synergies. Can reach 30s without additional M&A; doors not closed but focused on integration. Market is huge, opportunity abundant but will be disciplined.

Respect Abridge but 30 vendors aspiring to platform; not all will execute. IKS has built competitive moat. Competitive intensity will increase, but we're confident in value proposition. Renewal deals signed at healthy prices (just closed 5-year lock-in). Pricing pressure exists but not the biggest issue; customers need to separate signal from noise.

Market growing 12%, IKS aspires to match or exceed via market share gains. Headcount growing slower (4.2% YoY) than revenue (12% YoY), supporting margin expansion. Guidance explicitly disclaimed as 'aspiration' multiple times.

Post-close assessment: revenue reset from $340M to $300M annualized due to rev rec change, service line exit, customer discounts. Management stated need for 2-3 quarters to understand growth drivers and articulate forward outlook.

Starting point: IKS 33%, TruBridge 22-23%; blended ~26-27% initially. Levers: offshore model transformation, technology leverage, SG&A synergies. Execution-dependent; no quarterly milestones provided.

Q1 tax rate 22.4%; management comfortable this will stay in 22-23% range for legacy IKS; will provide combined tax guidance next quarter.

Management mentioned continued investment in AI/SLM training, knowledge graphs, and offshore model; no capex targets disclosed.

TruBridge integration just 1 month old at call date. Management must execute: offshore model shift, technology leverage, SG&A synergies. Margin target of early-30s requires flawless execution. If delayed/failed, FY30 INR 3,000 Cr EBITDA goal at risk.

TruBridge revenue reset from $340M to $300M annualized post-close. Drivers: $2-3M/qtr rev rec conservatism, $8M/qtr service line exit (IT, early-out), $2-3M/qtr customer discounts to accelerate transformation. If discounts persist or customer churn occurs, revenue could compress further.

Abridge launched pre-peri-post-visit platform June 2026. Management acknowledged 30 vendors aspiring to platform; some will win, some lose. Pricing pressure acknowledged in large health system renewals. IKS relies on KLAS/Black Book ratings and comprehensive system-of-action moat; if competitors close feature gaps or undercut pricing significantly, market share at risk.

Management emphasizing AI/SLM strategy as core long-term differentiator (FY30 target hinges on it). However, all components are nascent: 5M+ patient dataset from TruBridge just being structured for training, SLM models not yet deployed at scale, knowledge graphs from ARAI acquisition still early. No quantified cost savings or revenue uplift from AI yet. Execution risk high if AI strategy underperforms or competitors leapfrog.

Top 10 customer revenue growing, but concentration held flat at ~35-40% (implied). Vintage 6+ years shows high stickiness. However, large health system renewals require competitive strength; if any top customer migrates to Abridge or other platform, revenue impact material. Land-and-expand model depends on account penetration at existing customers.